RTP Mobile Logo
Submitted by web@researchtop... on Thu, 04/16/2020 - 16:15

 

Topic 1: Integrating PARP inhibitors into the treatment algorithm for patients with prostate cancer (PC)
Topic 2: Role of PARP enzymes in DNA damage repair and mechanism of action of PARP inhibitors
Topic 3: Genetic testing for patients with PC
Topic 4: Correlation between Gleason score and incidence of DNA repair gene mutations in patients with localized PC
Topic 5: Role of platinum-based chemotherapy for patients with PC and DNA repair gene mutations
Topic 6: Sequencing PARP inhibitors and chemotherapy for patients with PC and DNA repair gene mutations
Topic 7: Case (Dr Antonarakis): A man in his mid-40s with castration-resistant PC (CRPC), a BRCA2 mutation and lung metastases attains an excellent response to olaparib on a clinical trial
Topic 8: Tolerability and side effects of PARP inhibitors
Topic 9: Case (Dr Antonarakis): A man in his late 40s with metastatic hormone-sensitive PC and biallelic BRCA2 mutations receives PARP inhibitor monotherapy on a clinical trial
Topic 10: Perspective on the potential use of PARP inhibitor monotherapy in the first-line setting for patients with hormone-sensitive PC and DNA repair gene mutations
Topic 11: Tolerability of PARP-inhibitor monotherapy in the first-line setting
Topic 12: Case (Dr Sartor): A man in his late 60s with metastatic CRPC (mCRPC) and a germline BRCA2 mutation receives olaparib
Topic 13: Dosing and PARP trapping activity of PARP inhibitors
Topic 14: Case (Dr Agarwal): A man in his late 60s with progressive mCRPC is enrolled on the TALAPRO-2 trial of enzalutamide with or without talazoparib
Topic 15: Efficacy and tolerability of PARP inhibitors alone or in combination with endocrine therapy
Topic 16: Response to PARP inhibitors in patients with PALB2, FANCA and RAD51 mutations; clinical care of patients with PC during the COVID-19 pandemic

 
FACULTY
 
Neeraj Agarwal, MD
Professor of Medicine
Huntsman Cancer Institute
Presidential Endowed Chair
in Cancer Research
Director
Genitourinary Oncology Program
Huntsman Cancer Institute
University of Utah
Salt Lake City, Utah
 
Emmanuel S Antonarakis, MD
Professor of Oncology and Urology
Johns Hopkins University
The Sidney Kimmel
Comprehensive Cancer Center
Baltimore, Maryland
 
A Oliver Sartor, MD
CE and Bernadine Laborde
Professor for Cancer Research
Medical Director
Tulane Cancer Center
Assistant Dean for Oncology
Tulane Medical School
New Orleans, Louisiana
 
MODERATOR
 
Neil Love, MD
Research To Practice
Miami, Florida